Cognitive & Nootropic

FGL

NCAM FG-loop · FG loop peptide · FGL peptide

Synthetic peptide from the NCAM FG loop, studied as an FGFR-modulating neural cell-adhesion mimetic. Research-chem nootropic SKU. Not a stroke drug. Distinct from P21 (CNTF-derived), which we already list.

Not FDA-approved - research chemical

Quick answer

What it is: Synthetic peptide from the NCAM FG loop, studied as an FGFR-modulating neural cell-adhesion mimetic.

Typical research dose: Research; vendor nasal/SC ranges are not a label

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Low

Typical research dose

Research; vendor nasal/SC ranges are not a label

Frequency

Not established

Half-life

Short (SKU unpublished)

Common vials

5 mg / 10 mg

CAS

N/A

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Cognition3/10
Published peptide plus preclinical neuro literature. Not a human nootropic RCT.

Compound card

Sequence: NCAM FG-loop peptide
Class: FGFR-interacting NCAM mimetic (not P21)
Formula: NCAM FG-loop peptide
Status: Not FDA-approved · research use

Dose it

5 mg + 2.5 mL BAC water → 2 mg/mL · 200 mcg ≈ 10 units (U-100)

Open in calculator

How it works

FGL is a peptide from the NCAM FG loop, published as an FGFR-interacting neural cell-adhesion mimetic. It is a different molecule from P21 (CNTF-derived), which we already list.

Nootropic vendor SKUs are not stroke or dementia care.

Research Use Cases

✓Nootropic research identity: Low

Dosing

Phase	Dose	Frequency	Notes
Research	Vendor ranges only	n/a	Not a label.

Administration

Route / form

Intranasal or SC (vendor)

Timing

Not established.

Empty stomach?

No - Food timing is not critical.

Timeline

Unknown in consumers

Neural-plasticity papers are not a stack timeline.

Who it is for

Nootropic research identity

Low

Listed because Pepdex-class catalogs include it. Distinct from P21.

Reconstitution

Vial

5 mg

Diluent

2.5 mL

Concentration

2 mg/mL

Per Unit (100u syringe)

20 mcg

Dose of 200 mcg = 10 units on a 100-unit insulin syringe

Safety & Considerations

Research peptide. FGF-adjacent signaling is not a toy. Not a substitute for neurology care.

Regulatory & Legal Status

FDA Status (US)

Research Only

NCAM FG-loop mimetic. Research-only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

The FGL literature is identity/mechanism, not a reconstitution hobby.
This site will not treat stroke or dementia from this leaf.

Verdict

FGL is an NCAM FG-loop peptide, not P21, not Semax. A paper exists. A stroke protocol does not.

Interactions & Contraindications

Research peptide. FGF-adjacent signaling is not a toy. Not a substitute for neurology care.

FGL vs. P21

Canonical comparison: FGL vs P21

Attribute	FGL	P21
Origin	NCAM FG loop	CNTF-derived (P021)
Claimed job	FGFR / neural CAM mimetic	Neurotrophic CNTF fragment
Human PK	SKU unpublished	Estimated / research

Verdict: Two different nootropic research peptides. FGL is not P21 with a new name.

Frequently Asked Questions

Is FGL the same as P21?▼

No. FGL is NCAM FG-loop. P21 is CNTF-derived. Separate IDs.

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library